These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
683 related articles for article (PubMed ID: 12783654)
21. [Impact of anti-tuberculosis drug resistance on treatment outcome of pulmonary tuberculosis patients receiving directly observed treatment strategy in Henan Province, China]. Wang GJ; Xu JY; Wang GB; Zhen XA; Gao SY; Du CM Zhonghua Jie He He Hu Xi Za Zhi; 2006 Aug; 29(8):527-30. PubMed ID: 17074265 [TBL] [Abstract][Full Text] [Related]
22. [Mycobacterium tuberculosis resistance to antitubercular agents in Antananarivo in 2000]. Ratsirahonana O; Rasolofo Razanamparany V; Rasolonavalona T; Rakotonirina V; Rakotoarisaonina A; Rakotoherisoa A; Ralamboson M; Cauchoix B; Rakotondramarina D; Ramarokoto H Arch Inst Pasteur Madagascar; 2002; 68(1-2):44-7. PubMed ID: 12643091 [TBL] [Abstract][Full Text] [Related]
23. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. Park SK; Lee WC; Lee DH; Mitnick CD; Han L; Seung KJ Int J Tuberc Lung Dis; 2004 Mar; 8(3):361-8. PubMed ID: 15139476 [TBL] [Abstract][Full Text] [Related]
24. A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre. Int J Tuberc Lung Dis; 1997 Dec; 1(6):509-17. PubMed ID: 9487448 [TBL] [Abstract][Full Text] [Related]
25. [Treatment outcomes of multidrug-resistant tuberculosis--comparison between success and failure cases]. Shigetoh E; Murakami I; Yokosaki Y; Kurimoto N Kekkaku; 2001 Dec; 76(12):723-8. PubMed ID: 11806128 [TBL] [Abstract][Full Text] [Related]
26. Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide (Rifater) in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a five-year follow-up report. Teo SK Int J Tuberc Lung Dis; 1999 Feb; 3(2):126-32. PubMed ID: 10091877 [TBL] [Abstract][Full Text] [Related]
27. [Long-term efficacy of full course intermittent short-course chemotherapy on new smear positive tuberculosis patients]. Zhonghua Jie He He Hu Xi Za Zhi; 1997 Jun; 20(3):164-6. PubMed ID: 10072822 [TBL] [Abstract][Full Text] [Related]
28. [Follow-up study of short course chemotherapy of pulmonary tuberculosis complicated with diabetes mellitus]. Kameda K; Kawabata S; Masuda N Kekkaku; 1990 Dec; 65(12):791-803. PubMed ID: 2077255 [TBL] [Abstract][Full Text] [Related]
29. [Results of a therapeutic trial comparing a 6-month regimen to a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Final report: results 3 years after the onset of treatment]. Berkani M; Chaulet P; Darbyshire JH; Nunn A; Fox W Rev Mal Respir; 1986; 3(2):73-85. PubMed ID: 3726263 [TBL] [Abstract][Full Text] [Related]
30. [Long-term results of treatment for drug-resistant pulmonary tuberculosis in socially adapted patients]. Khodashova ML; Iuditskiĭ MV; Semenova OV Probl Tuberk Bolezn Legk; 2004; (3):26-8. PubMed ID: 15338896 [TBL] [Abstract][Full Text] [Related]
31. [Analysis of causes of drug resistance and therapeutic effects on 27 multi-drug resistant pulmonary tuberculosis patients]. Ye Z; Pei X; Yang Y Zhonghua Jie He He Hu Xi Za Zhi; 1997 Aug; 20(4):234-6. PubMed ID: 10072811 [TBL] [Abstract][Full Text] [Related]
32. Multidrug-resistant tuberculosis at Srinagarind Hospital, Khon Kaen, Thailand. Reechaipichitkul W Southeast Asian J Trop Med Public Health; 2002 Sep; 33(3):570-4. PubMed ID: 12693593 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients. Prasad R; Verma SK; Sahai S; Kumar S; Jain A Indian J Chest Dis Allied Sci; 2006; 48(3):183-6. PubMed ID: 18610675 [TBL] [Abstract][Full Text] [Related]
34. Tuberculosis drug resistance and treatment outcomes under DOTS settings in large cities in the Philippines. Ohkado A; Aguiman L; Adlawan S; Baring E; Quirante O; Suchi M; Endo S; Fujiki A; Mori T Int J Tuberc Lung Dis; 2006 Mar; 10(3):283-9. PubMed ID: 16562708 [TBL] [Abstract][Full Text] [Related]
35. [Treatment results of rifampicin (RFP) resistant isoniazid (INH) susceptible tuberculosis, a hospital based study]. Yoshiyama T; Ogata H; Ito K; Aono A; Wada M Kekkaku; 2007 Feb; 82(2):95-101. PubMed ID: 17373318 [TBL] [Abstract][Full Text] [Related]
37. Multidrug-resistant tuberculosis: long-term treatment outcome in the Netherlands. Geerligs WA; Van Altena R; De Lange WCM ; Van Soolingen D; Van Der Werf TS Int J Tuberc Lung Dis; 2000 Aug; 4(8):758-64. PubMed ID: 10949328 [TBL] [Abstract][Full Text] [Related]
38. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up. Su WJ; Perng RP Int J Tuberc Lung Dis; 2002 Nov; 6(11):1029-32. PubMed ID: 12475151 [TBL] [Abstract][Full Text] [Related]
39. Study of drug resistance in previously treated tuberculosis patients in Gujarat, India. Shah AR; Agarwal SK; Shah KV Int J Tuberc Lung Dis; 2002 Dec; 6(12):1098-101. PubMed ID: 12546118 [TBL] [Abstract][Full Text] [Related]